SEC Form 4 · accession 0001209191-18-061113
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lauren M Sabella
Officer — Chief Commercial Officer
Period of report
Dec 3, 2018
Accepted (ET)
Dec 6, 2018 · 8:31 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Dec 3, 2018 | S | 1,072 | $20.2012 | D | 5,687 | D | |
| Common StockF3,F4 | Dec 3, 2018 | S | 4,119 | $20.6557 | D | 1,568 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sales pursuant to a 10b5-1 plan. These sales are primarily intended to cover the tax liability resulting from restricted stock vesting.
- F2The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.0600 to $20.2500 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Sales pursuant to a 10b5-1 plan.
- F4The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $20.2500 to $20.7900 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.